7.            Accrued Expense

As of March 31, 2026, current liabilities included accrued expenses of $3.0 million, comprised primarily of accrued clinical trial expenses of $2.5 million, accrued salaries and benefits expense of $0.2 million and other accrued expenses of $0.3 million. As of December 31, 2024, current liabilities included accrued expenses of $1.9 million, comprised primarily of expenses related to the Company’s clinical trial for prexigebersen in AML of $1.5 million, accrued employee vacation of $0.1 million, professional and consulting fees of $0.1 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million.